Profile avatar
mrivas03.bsky.social
Stanford professor. Interested in human genetics, statistical modeling, entrepreneurship. https://rivaslab.stanford.edu
25 posts 214 followers 409 following
Prolific Poster
Conversation Starter

Excited to finally share that our paper looking at the effect of rare non-coding variants using WGS on circulating protein levels in the UKB has been released in Nature Genetics @naturegenet.bsky.social! We now analyse the full 3,000 circulating proteins in all 50,000 individuals rdcu.be/ea16i

Check out our web tool for searching for interactors of your favorite cell surface protein, developed by undergrad Pinyu Liao and postdoc postdoc Brendan Floyd @stanford-chemh.bsky.social cellsurfacemap.org

Happy to share a new preprint, to which I provided a minor contribution. Using genetic data from ~100k human embryos, we found ~1k that were haploid or triploid. We describe a thorough characterization of these embryos, with many interesting findings 🧵 1/9 www.biorxiv.org/content/10.1...

music.apple.com/us/album/ele...

Spatial proteomics in human carotid atherosclerotic plaques (N=118). A great weekend read❗️ 👉subregions isolated with microdissection (lipid core, fibrous cap, tunica media) 👉mass-spec proteomics 👉proteome-defined subclusters across subregions 👉biological enrichment across subclusters 1/2

Indeed. Index SNP is missed with ceiling

Our paper on Efficient regression for population-scale genome sequencing studies is published and online 1.5 minutes on a single machine academic.oup.com/bioinformati...

Fantastic

🎇Our new paper in @ScienceMagazine : Kidney Multiome-Based Genetic Scorecard Reveals Convergent Coding and Regulatory Variants. @Hongbo919Liu science.org/doi/10.1126/...

New in the February 6, 2025, issue of NEJM: Iptacopan in IgA Nephropathy (APPLAUSE-IgAN phase 3 trial) nej.md/3UmrOkh Atrasentan in Patients with IgA Nephropathy (ALIGN phase 3 trial) nej.md/3NzvISW Liraglutide for Children with Obesity (SCALE Kids phase 3a trial) nej.md/3MBP1uc #MedSky

Our paper led by J. Shin & A. Small evaluating the longitudinal penetrance of HCM alleles in the Mass General Brigham Biobank www.sciencedirect.com/science/arti... @jaccjournals.bsky.social #JACCAdv @broadinstitute.org @cgm-mgh.bsky.social @mgbresearch.bsky.social

This is a great write up by Bob Carpenter (read the PDF document)

music.apple.com/us/album/i-f...

Generalized linear neural network models statmodeling.stat.columbia.edu/2025/02/04/g...

Happy to see this online. We assess the genetic contribution to disease progression (as opposed to susceptibility). Time-to-event models are quite relevant here.

Prevalence and disease risks for male and female sex chromosome trisomies: a registry-based phenome-wide association study in 1.5 million participants of MVP, FinnGen, and UK Biobank https://www.medrxiv.org/content/10.1101/2025.01.31.25321488v1

Haplotype rather than single causal variants effects contribute to regulatory gene expression associations in human myeloid cells https://www.biorxiv.org/content/10.1101/2025.01.30.635675v1

New in the January 30, 2025, issue of NEJM: Tirzepatide for Heart Failure and Obesity (SUMMIT trial) nej.md/4hRGaTY Continuation of Oral Anticoagulation during TAVI (POPular PAUSE TAVI trial) nej.md/3XllHys Lentiviral Gene Therapy for Hemophilia A nej.md/3Vk5xUA #MedSky

Two patients with congenital generalized lipodystrophy type 1 due to a variant in AGPAT2 (c.589-2A→G) who had been receiving insulin and metreleptin were switched to tirzepatide and were successfully weaned off other therapy. Read the full correspondence: nej.md/40Rznmz #MedSky #EndoSky

😮

Modern GWAS can identify 1000s of significant hits but it can be hard to turn this into biological insight. What key cellular functions link genetic variation to disease? I'm very excited to present our new work combining associations and Perturb-seq to build interpretable causal graphs! A 🧵

Unified meta regression models for rare variant association studies https://www.biorxiv.org/content/10.1101/2025.01.23.634522v1

Happy to share our manuscript “Unified meta regression models for rare variant association studies” www.biorxiv.org/content/10.1...

Abstract Submission Deadline for ESHG 2025 is on January 30, 2025 at 23:59 CET and it is swiftly approaching. Please apply! Milan is waiting for you.

ESHG Abstract Deadline Reminder! The Submission Deadline for #ESHG2025 is in a week (Jan 30)! Please join us this spring (May 24-27) in Milan, Italy, for another fun and exciting ESHG conference! Learn more at 2025.eshg.org Please retweet. #Genetics #ScienceConference #ESHG #ESHG2025

Fantastic!

Fantastic new work from @sethasharp and @annagloyn.bsky.social . T1D GRS for the clinic may be getting close !

APOC3 inhibition for the win

In Brief: The @fda.gov approves Ionis Pharmaceuticals’ triglyceride-lowering rare disease drug #Tryngolza www.nature.com/articles/s41... rdcu.be/d6V0J

Like most people, when I need a distraction I dive deep into @gwascatalog.bsky.social. This time I was rewarded with pQTLs from the recent CSF study www.nature.com/articles/s41... Do CSF pQTLs have a different distance distribution from other molecular QTLs?

Anyone out there with experience analyzing time series/ wave like data? I have a project that needs a bit of help

😮👀 👍🏼

Hello, Blue! :-)